• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Akoya BioSciences Inc. (Amendment)

    2/14/24 4:09:03 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AKYA alert in real time by email
    SC 13G/A 1 tm246170d2_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)*

     

    Akoya Biosciences, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.00001
    (Title of Class of Securities)
     
    00974H104
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    x Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.  00974H104

     

    1.  

    Name of Reporting Persons

     

    Telegraph Hill Partners III, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.  

    SEC Use Only

     

    4.  

    Citizenship or Place of Organization

     

    State of Delaware

    Number of Shares

    Beneficially Owned

    By Each Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    17,675,247(1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    17,675,247 (1)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    17,675,247 (1)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

    36.0%(1)(2)

    12.  

    Type of Reporting Person (See Instructions)

    PN

             

    (1)Includes (i) 15,937,535 shares of common stock held by Telegraph Hill Partners III, L.P. and (ii) 1,737,712 shares of common stock held by THP III Affiliates Fund, LLC.
    (2)Consists of 49,076,173 shares of Common Stock of the Issuer outstanding on October 31, 2023, based on information publicly disclosed by the Issuer.

     

     

     

     

     

    CUSIP No.  00974H104

     

    1.  

    Name of Reporting Persons

     

    THP III Affiliates Fund, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.  

    SEC Use Only

     

    4.  

    Citizenship or Place of Organization

     

    State of Delaware

    Number of Shares

    Beneficially Owned

    By Each Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    17,675,247(1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    17,675,247 (1)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    17,675,247 (1)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

    36.0%(1)(2)

    12.  

    Type of Reporting Person (See Instructions)

    PN

             
    (1)Includes (i) 15,937,535 shares of common stock held by Telegraph Hill Partners III, L.P. and (ii) 1,737,712 shares of common stock held by THP III Affiliates Fund, LLC.
    (2)Consists of 49,076,173 shares of Common Stock of the Issuer outstanding on October 31, 2023, based on information publicly disclosed by the Issuer.

     

     

     

     

     

    CUSIP No.  00974H104

     

    1.  

    Name of Reporting Persons

     

    Telegraph Hill Partners III Investment Management, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.  

    SEC Use Only

     

    4.  

    Citizenship or Place of Organization

     

    State of Delaware

    Number of Shares

    Beneficially Owned

    By Each Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    17,675,247(1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    17,675,247 (1)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    17,675,247 (1)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

    36.0%(1)(2)

    12.  

    Type of Reporting Person (See Instructions)

    PN

             
    (1)Includes (i) 15,937,535 shares of common stock held by Telegraph Hill Partners III, L.P. and (ii) 1,737,712 shares of common stock held by THP III Affiliates Fund, LLC.
    (2)Consists of 49,076,173 shares of Common Stock of the Issuer outstanding on October 31, 2023, based on information publicly disclosed by the Issuer.

     

     

     

     

     

    CUSIP No.  00974H104

     

    1.  

    Name of Reporting Persons

     

    Telegraph Hill Partners Management Company, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.  

    SEC Use Only

     

    4.  

    Citizenship or Place of Organization

     

    State of Delaware

    Number of Shares

    Beneficially Owned

    By Each Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    17,675,247(1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    17,675,247 (1)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    17,675,247 (1)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

    36.0%(1)(2)

    12.  

    Type of Reporting Person (See Instructions)

    PN

             
    (3)Includes (i) 15,937,535 shares of common stock held by Telegraph Hill Partners III, L.P. and (ii) 1,737,712 shares of common stock held by THP III Affiliates Fund, LLC.
    (4)Consists of 49,076,173 shares of Common Stock of the Issuer outstanding on October 31, 2023, based on information publicly disclosed by the Issuer.

     

     

     

     

    Item 1(a). Name of Issuer
       
      Akoya Biosciences, Inc. (the “Issuer”)
       
    Item 1(b). Address of the Issuer’s Principal Executive Offices
       
      100 Campus Drive, 6th Floor, Marlborough, MA 10752
       
    Item 2(a). Names of Persons Filing
       
      This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

      (i) Telegraph Hill Partners III, L.P.
         
      (ii) THP III Affiliates Fund, LLC
         
      (iii) Telegraph Hill Partners III Investment Management, LLC
         
      (iv) Telegraph Hill Partners Management Company, LLC

     

    Item 2(b). Address of the Principal Business Office, or if none, Residence:
       
      The address of the principal business and principal office of each of the Reporting Persons is 360 Post Street, Suite 601, San Francisco, California 94108.
       
    Item 2(c). Citizenship

     

      (i) Telegraph Hill Partners III, L.P. is a Delaware limited partnership.
         
      (ii) THP III Affiliates Fund, LLC is a Delaware limited liability company.
         
      (iii) Telegraph Hill Partners III Investment Management, LLC is a Delaware limited liability company.
         
      (iv) Telegraph Hill Partners Management Company, LLC is a Delaware limited liability company.

     

    Item 2(d). Title of Class of Securities
       
      Common stock, par value $0.00001 per share

     

    Item 2(e). CUSIP Number
       
      00974H104

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

      Not applicable.

     

    Item 4.

    Ownership

     

    (a)       Amount Beneficially Owned:

     

    Telegraph Hill Partners III, L.P.

     

    15,937,535 shares of common stock are held of record by Telegraph Hill Partners III, L.P. (“THP III”). Telegraph Hill Partners III Investment Management, LLC (“THP IM”) is the general partner of THP III. Telegraph Hill Partners Management Company, LLC (“THPMC”) is the manager of THP IM.

     

    THP III Affiliates Fund, LLC

     

    1,737,712 shares of common stock are held of record by THP III Affiliates Fund, LLC (“THP III AFF”). THP IM is the manager of THP III AFF. THPMC is the manager of THP IM.

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable.
       
     Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group
       
      See Exhibit B.
       
    Item 9. Notice of Dissolution of Group
       
      Not applicable.
       
    Item 10. Certification
       
      By signing below each of the undersigned certifies that, to the best of its or his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATE: February 14, 2024

     

     

    Telegraph Hill Partners III, L.P.

    By: Telegraph Hill Partners III Investment Management, LLC

    Its: General Partner

    By: Telegraph Hill Partners Management Company LLC

    Its: Manager

     

      By: /s/ Rob Hart
        Rob Hart
        Partner

     

     

    THP III Affiliates Fund, LLC

    By: Telegraph Hill Partners III Investment Management, LLC

    Its: Manager

    By: Telegraph Hill Partners Management Company LLC

    Its: Manager

     

      By: /s/ Rob Hart
        Rob Hart
        Partner

     

     

    Telegraph Hill Partners III Investment Management, LLC

    By: Telegraph Hill Partners Management Company LLC

    Its: Manager

     

      By: /s/ Rob Hart
        Rob Hart
        Partner

     

     

    Telegraph Hill Partners Management Company, LLC

     

      By: /s/ Rob Hart
        Rob Hart
        Partner

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations

    (See 18 U.S.C. 1001)

     

     

     

      

    EXHIBIT INDEX

     

         
    Exhibit
    Number
      Description
       
    A   Joint Filing Agreement (incorporated by reference to Exhibit A to the Schedule 13G filed on May 28, 2021).
       
    B   Group disclosure (incorporated by reference to Exhibit B to the Schedule 13G filed on May 28, 2021).

     

     

     

    Get the next $AKYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKYA

    DatePrice TargetRatingAnalyst
    11/15/2024$7.00 → $5.00Buy → Hold
    Craig Hallum
    8/6/2024Overweight → Equal-Weight
    Morgan Stanley
    8/6/2024Buy → Neutral
    BTIG Research
    8/6/2024Overweight → Neutral
    JP Morgan
    6/21/2024$7.50Buy
    Craig Hallum
    12/14/2023Neutral
    Guggenheim
    7/5/2023$18.00Overweight
    JP Morgan
    2/2/2023$14.00Buy
    UBS
    More analyst ratings

    $AKYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO Ek John Frederick covered exercise/tax liability with 16,432 shares, decreasing direct ownership by 6% to 248,202 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      4/3/25 5:14:37 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President and CEO Mckelligon Brian covered exercise/tax liability with 7,550 shares, decreasing direct ownership by 2% to 420,126 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      3/25/25 6:34:07 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Business Officer Ramachandran Niro Ph.D covered exercise/tax liability with 2,310 shares, decreasing direct ownership by 0.80% to 287,210 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      3/25/25 6:32:42 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Akoya Biosciences downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Akoya Biosciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously

      11/15/24 8:33:16 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences downgraded by Morgan Stanley

      Morgan Stanley downgraded Akoya Biosciences from Overweight to Equal-Weight

      8/6/24 12:17:30 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences downgraded by BTIG Research

      BTIG Research downgraded Akoya Biosciences from Buy to Neutral

      8/6/24 6:28:51 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Leadership Updates

    Live Leadership Updates

    See more
    • Akoya Biosciences Announces Leadership Transition

      Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the company's new Chief Financial Officer, effective immediately. Mr. Driscoll will continue to serve as a consultant of the company as Akoya executes a seamless transition between the two leaders. Mr. Driscoll joined Akoya in April 2019 and has overseen the company's financ

      3/20/23 4:00:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel

      MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. "We are excited to welcome Jennifer to our leadership team," said Brian McKelligon, Chief Executive Officer of Akoya. "Her deep legal expertise and insight will be invaluable as we continue to advance our spatial biology platform and establish additional partnerships to support discovery, translational, and clinical markets." Ms. Kamocsay most recently served as Gen

      2/28/23 8:00:00 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer

      MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company's Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya's strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company's vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist who served as the Senior Medical Director for Roche Tissue Diagnostics Personalized Health Care Solutions (PHCS). As the

      4/19/22 8:05:00 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Financials

    Live finance-specific insights

    See more

    $AKYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $AKYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AKYA
    SEC Filings

    See more
    • Akoya Biosciences Reports First Quarter 2025 Financial Results

      MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

      5/12/25 4:05:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

      MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions," said Brian McKelligon, CEO of Akoya. "In 2024, Akoya achieved multiple milestones, i

      3/17/25 4:00:00 PM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

      Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined cash position of approximately $175 million with no expected debt at closing to pursue future growth initiatives Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ

      1/10/25 7:00:00 AM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Reports First Quarter 2025 Financial Results

      MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

      5/12/25 4:05:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

      It is Deeply Disturbing, in Kent Lake's View, that the Company's Amended Agreement to Merge with Akoya Deprives Quanterix Shareholders of Ability to Vote on the Transaction Believes Quanterix's Maneuvers Further Demonstrate the Need for New Directors with Real Credibility and Accountability to Shareholders – And Will Press on With Nominations of Three Highly Qualified Board Candidates Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the "Amended Merger Agreement") relat

      4/30/25 8:00:00 AM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix and Akoya Biosciences Announce Amended Merger Agreement

      Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ:AKYA), The Spatial Biology Company®, today announced an amendment to the terms of their previously announced merger agreement. Under the amended terms, Quanterix will issue approximately 7.76 million shares of its common stock and pay $20 million in cash to Akoya shareholders. Each Akoya share will receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock. With the amended exchange ratio, Quanterix will issue over 9 million fewer

      4/29/25 7:00:00 AM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Akoya BioSciences Inc.

      SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

      11/4/24 7:39:24 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Akoya BioSciences Inc.

      SC 13G - Akoya Biosciences, Inc. (0001711933) (Subject)

      8/28/24 10:45:17 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Akoya BioSciences Inc. (Amendment)

      SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

      2/14/24 4:09:03 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 425 filed by Akoya BioSciences Inc.

      425 - Akoya Biosciences, Inc. (0001711933) (Subject)

      5/12/25 4:11:23 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Akoya Biosciences, Inc. (0001711933) (Filer)

      5/12/25 4:10:15 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 425 filed by Akoya BioSciences Inc.

      425 - Akoya Biosciences, Inc. (0001711933) (Subject)

      5/12/25 4:08:50 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials